

U.S.S.N. 10/747,715
Attorney Docket No. 133658-2
Page 6 of 6

REMARKS

In the Office Action mailed from the United States Patent and Trademark Office on May 3, 2006, claims 58-81 were subjected to an election of species requirement. Specifically, Applicants were required to identify the amyloid related disease, the imaging agent, the soluble A-beta, the imaging agent label, and the non-invasive detection method. Applicants hereby elect the following species and identify the claims readable thereon:

Species	Claims
Amyloid related disease: Alzheimer's	58-81
Imaging agent: antibody or antibody fragment	58-80
A-beta: oligomers of up to 24 A-beta peptides	58-80
Labels: radioisotopes	58-64, 67-72, 74, 77-80
Detection method: positron emission tomography	58-64, 67-72, 74, 77-80

Although Applicants do not believe that any extension of time or fee is required to have the present paper entered, Applicants hereby authorize the Commissioner of Patents to charge Applicants' Deposit Account No. 07-0868 for any required fee.

If Examiner Jones wishes to discuss the present patent application with Applicants' attorney, she is invited to contact the undersigned at 518-387-6304.

Respectfully submitted,



Maureen A. Bresnahan
Attorney for Applicants
Reg. No. 44,559

June 5, 2006
General Electric Company
Building K1, Room 3A64
Niskayuna, New York 12309
Telephone: (518) 387-6304 or
(518) 387-7122